Additional variables that could be validated as pre-HCT risk factors in pediatric patients
| Cardiac |
| Prolonged QTc |
| Endocrinopathies |
| Metabolic syndrome |
| Thyroid dysfunction |
| Low cortisol production |
| Growth delays |
| Hypertriglyceridemia |
| Low activity levels/sedentary lifestyle |
| Gastrointestinal |
| Pneumatosis |
| Pancreatitis |
| Poorly-diversified microbiome |
| Hypoalbuminemia/hypoproteinemia |
| Genetic variants (HLA and non-HLA genes) |
| Intensive care |
| Number of hospitalizations |
| Extracorporeal membrane oxygenation |
| Iron overload |
| Number of red blood cell transfusions received |
| T2*MRI |
| Neuropsychiatric concerns |
| Developmental delay |
| Isolation |
| Poor resiliency |
| Behavior concerns |
| Attention deficit hyperactivity disorders |
| Poor sleep patterns |
| Low scores on validated, age-appropriate patient-reported outcomes |
| Pain requiring scheduled opioid medications |
| Predisposition to transplant-associated microangiopathy |
| High inflammatory markers (e.g., C reactive protein) preceding conditioning |
| High baseline terminal complement system pathway factors (eg, soluble C5b-9) |
| High urine protein to creatinine ratio |
| Socioeconomic factors/access to care |
| Noncompliance with treatments |
| Homelessness |
| Poor family support system |
| Social isolation |
| Food insecurity |
| Financial toxicity/insurance concerns |
| Amount of school/work missed |
| Marginalized populations/disparities in care |
| Vitamin and mineral deficiencies |
| Vitamin D |
| Iron |
| Zinc |
| Cardiac |
| Prolonged QTc |
| Endocrinopathies |
| Metabolic syndrome |
| Thyroid dysfunction |
| Low cortisol production |
| Growth delays |
| Hypertriglyceridemia |
| Low activity levels/sedentary lifestyle |
| Gastrointestinal |
| Pneumatosis |
| Pancreatitis |
| Poorly-diversified microbiome |
| Hypoalbuminemia/hypoproteinemia |
| Genetic variants (HLA and non-HLA genes) |
| Intensive care |
| Number of hospitalizations |
| Extracorporeal membrane oxygenation |
| Iron overload |
| Number of red blood cell transfusions received |
| T2*MRI |
| Neuropsychiatric concerns |
| Developmental delay |
| Isolation |
| Poor resiliency |
| Behavior concerns |
| Attention deficit hyperactivity disorders |
| Poor sleep patterns |
| Low scores on validated, age-appropriate patient-reported outcomes |
| Pain requiring scheduled opioid medications |
| Predisposition to transplant-associated microangiopathy |
| High inflammatory markers (e.g., C reactive protein) preceding conditioning |
| High baseline terminal complement system pathway factors (eg, soluble C5b-9) |
| High urine protein to creatinine ratio |
| Socioeconomic factors/access to care |
| Noncompliance with treatments |
| Homelessness |
| Poor family support system |
| Social isolation |
| Food insecurity |
| Financial toxicity/insurance concerns |
| Amount of school/work missed |
| Marginalized populations/disparities in care |
| Vitamin and mineral deficiencies |
| Vitamin D |
| Iron |
| Zinc |
HLA, human leukocyte antigen; MRI, magnetic resonance imaging. While not exhaustive, many of these entities have been evaluated as possible contributors to poor health and/or medical complications in transplant and/or nontransplant patients and may contribute to acute and long-term complications in areas of human health that could impact NRM and OS after HCT in youths.